Learn More
Model transformations form a key part of MDA (Model-Driven Architecture). Most of the studies deal with the transformations from PIM (Platform-Independent Model) to PSM (Platform-Specific Model) and PSM to Code, but very few deal with the transformation from CIM (Computation-Independent Model) to PIM. This last transformation usually depends on business(More)
Requirements capture is arguably the most important step in software engineering, and yet the most difficult and the least formalized one [Phalp and Shepperd 2000]. Enterprises build information systems to support their <i>business processes</i>. Software engineering research has typically focused on the development process, starting with user(More)
—Maritime surveillance of coastal regions requires the processing of data from a large number of heterogeneous surveillance sources. The generation of effective Maritime Domain Awareness requires that the tracks from these sources must be fused. An automated fusion process that supports Maritime Domain Awareness requires that the tracks from heterogeneous(More)
Experience has shown that poor strategy or bad tactics adopted when planning a software project influence the final quality of that product, even when the whole development process is undertaken with a quality approach. This paper addresses the quality attributes of the strategy and tactics of the software project plan that should be in place in order to(More)
BACKGROUND & AIMS Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against(More)
BACKGROUND Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b development in HIV-1 infection. METHODS Cenicriviroc(More)
INTRODUCTION Cenicriviroc (CVC), a once-daily, dual CCR5/CCR2 co-receptor antagonist, has completed Phase 2b development. CVC demonstrated favourable safety and similar efficacy compared with efavirenz (EFV) in Study 202 (NCT01338883); an ex vivo sub-analysis evaluated treatment effects on HIV entry, measured by intracellular HIV DNA declines, in subjects(More)